LWLiuxing Wang

Liuxing Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liuxing Wang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Chuntao Tian

    Department of Oncology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China

    1 shared publication
  • Danjie Chen

    Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China

    1 shared publication
  • Feng Wang

    Department of Oncology, The First Affiliated Hospital of Zhengzhou University

    1 shared publication
  • Jie Zhao

    Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

    1 shared publication
  • Jinhu Fan

    Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, China

    1 shared publication
  • Jun Wang

    Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies

    by Xue-Liang Zhou, Wen-Hua Xue, Xian-Fei Ding, Li-Feng Li, Meng-Meng Dou, Wei-Jie Zhang, Zhuan Lv, Zhi-Rui Fan, Jie Zhao, Liu-Xing Wang

    Objectives: The objective of this study was to evaluate the association between metformin therapy and the incidence of gastric cancer (GC) in patients with type 2 diabetes mellitus (T2DM).


  • Open Access

    TM4SF1 promotes the self-renewal of esophageal cancer stem-like cells and is regulated by miR-141

    by Lei Xue, Xiying Yu, Xingran Jiang, Xin Deng, Linlin Mao, Liping Guo, Jinhu Fan, Qinqxia Fan, Liuxing Wang, Shih-Hsin Lu

    TM4SF1 promotes the self-renewal of esophageal cancer stem-like cells and is regulated by miR-141


  • Open Access

    MiR-424-5p participates in esophageal squamous cell carcinoma invasion and metastasis via SMAD7 pathway mediated EMT

    by Feng Wang, Jun Wang, Xuan Yang, Danjie Chen, Liuxing Wang

    ESCC is a life-threatening disease due to invasion and metastasis in the early stage. Great efforts had been made to detect the molecular mechanisms which led to the invasion and metastasis in ESCC. Recent evidence had suggested that deregulation of miR-424-5p took an important role in cancers. However, its role and functional mechanism in ESCC had seldom been elucidated. The expression levels of miR-424-5p were detected in ESCC tissues and cell lines by real-time PCR methods. Then, the invasion, metastasis and proliferation ability of ESCC cell lines transfected with miR-424-5p mimics were analyzed separately by transwell invasion assay, wound healing assay and cell proliferation assay. Finally, the target gene of miR-424-5p was studied and verified by luciferase activity assay. And the role of miR-424-5p in EMT was also investigated by real-time PCR and western blot assay. We showed that the expression levels of miR-424-5p were decreased both in ESCC tissues and cell lines. Furthermore, the expression levels of miR-424-5p were negatively linked to lymph node metastasis in ESCC tissues. Restoration of miR-424-5p in EC-1 cells by using miR-424-5p mimics could decrease the invasion, metastasis and proliferation of EC-1 cells, indicating its role in inhibition on the invasion and metastasis ability of ESCC cells and tissues. In addition, we demonstrated that SMAD7 was a specific target gene for miR-424-5p by luciferase activity assay and miR-424-5p could not only negatively regulate SMAD7 expression but also participate in EMT via SMAD7, because overexpression of SMAD7 could partly enhance the miR-424-5p anti-EMT function. Our results described that miR-424-5p -SMAD7 pathway contributed to ESCC invasion and metastasis and up-regulation of miR-424-5p perhaps provided a strategy for preventing tumor invasion, metastasis.


  • Caveolin-1 affects tumor drug resistance in esophageal squamous cell carcinoma by regulating expressions of P-gp and MRP1

    by Song Zhang, Wenbo Cao, Mingjin Yue, Naigang Zheng, Tao Hu, Shengli Yang, Ziming Dong, Shixin Lu, Saijun Mo

    Esophageal squamous cell carcinoma (ESCC) is the most common cancer in China, and multidrug resistance (MDR) remains one of the biggest problems in ESCC chemotherapy. In this study, we aimed to investigate the mechanism of Caveolin-1, an integral membrane protein, on regulating ESCC MDR. First, immunohistochemistry was used to check the protein expression of Caveolin-1, MDR-related protein of P-glycoprotein (P-gp), and multidrug resistance protein 1 (MRP1) in 84 pathologically characterized ESCC tissues, matched adjacent tumor, and adjacent normal-looking tissues. The results showed that Caveolin-1 expression level was elevated in ESCC tissues than that of matched adjacent tumor and adjacent normal-looking tissues (P < 0.05), and the expression of Caveolin-1 has close correlation with P-gp and MRP1 during tumor genesis of ESCC (P = 0.034, P = 0.009, respectively). Then, Caveolin-1 overexpression and knockdown were used to investigate its effect on expressions of P-gp and MRP1 in ESCC cell line Ec9706. The messenger RNA (mRNA) and protein expression levels of P-gp and MRP1 were checked by real-time quantitative reverse transcription-PCR (qRT-PCR) and Western blot (WB). The results showed that Caveolin-1 overexpression significantly promotes the mRNA and protein expression of MRP1 (P < 0.05), while almost has no effect on the mRNA and protein expression of P-gp (P > 0.05); Cavoelin-1 knockdown inhibits the mRNA and protein expressions of both P-gp and MRP1 (P < 0.05). The similar result was found in another ESCC cell line Eca109. So, it is concluded that Caveolin-1 affects ESCC MDR by regulating the expressions of P-gp and MRP1; therefore, it can be taken as a significant marker and target in tumor therapy.


  • Open Access

    Prognostic Significance of Tumor-infiltrating CD8+ or CD3+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer

    by Chuntao Tian, Shixin Lu, Qingxia Fan, Weijie Zhang, Shunchang Jiao, Xiao Zhao, Zhiyong Wu, Liang Sun, Liuxing Wang

    Val (OS) of the patients. Methods: Paraffin-embedded tissue specimens from 129 NSCLC patients were retrospectively collected for immunostaining of CD8+, CD3+, and IL-2 expression. Clinicopathological and survival data were collected and analyzed using the Chi-squared test, Kaplan–Meier curves, and the log-rank test or the Cox regression model. Results: The data showed a significant inverse association between CD8+ T lymphocyte levels and IL-2 expression (r = −0.927; P = 0.000) and between the levels of CD8+ and CD3+ T lymphocytes (r = −0.722; P = 0.000), but a positive association between CD3+ T lymphocyte levels and IL-2 expression (r = 0.781; P = 0.000) in NSCLC tissues. Furthermore, the levels of CD3+ and CD8+ T lymphocytes and IL-2 expression were associated with tumor stage (P = 0.023, 0.006, and 0.031, respectively) and the level of CD8+ T lymphocytes was associated with the patient gender (P = 0.024). In addition, the levels of CD8+ T lymphocytes were associated with an unfavorable 5-year OS, whereas patients with high levels of CD3+ T lymphocytes in tumor lesions and IL-2-expressing tumors had significantly better 5-year OS rates than patients with low levels. Conclusions: The levels of CD8+ T cells in tumor lesions and IL-2 expression were both independent predictors of OS for these NSCLC patients. Thus, the detection of tumor-infiltrating CD3+ or CD8+ T lymphocytes and IL-2 expression could be useful to predict the prognosis of radically resected NSCLC patients....